Trials / Recruiting
RecruitingNCT07077044
The Effects of TTNS, TTNS Combined With PHUS, and Conventional Therapy With PHUS in the Treatment of PFC.
Transcutaneous Electrical Nerve Stimulation in Children With Functional Constipation Monitored by Pocket-sized Point-of-care Ultrasound.
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- Hadassah Medical Organization · Academic / Other
- Sex
- All
- Age
- 4 Years – 14 Years
- Healthy volunteers
- Accepted
Summary
This study is a randomized, controlled trial designed to evaluate the effects of transcutaneous tibial nerve stimulation (TTNS), TTNS combined with pocket-sized handheld ultrasound (PHUS), and conventional therapy with PHUS on children with functional constipation (FC). Participants will be stratified into three intervention arms (n=20 per group). FC will be defined based on the Rome IV diagnostic criteria, in the absence of organic or anatomical causes. Participants will be between 4 and 14 years old and will have experienced failure of conservative treatment for at least three months prior to enrollment. The primary outcomes include changes in rectal ultrasound parameters and symptom severity scores. Ultrasound assessments will be conducted by trained clinicians using standardized protocols. Monitoring for adverse events will be performed throughout the intervention phase. Safety considerations include predefined exclusion criteria, such as underlying neurological, metabolic, or cardiac conditions.
Detailed description
Eligibility Criteria Inclusion Criteria: Children aged 4 to 14 years. Diagnosis of functional constipation (FC) established prior to study enrollment. FC is defined according to the Rome IV diagnostic criteria, in the absence of identifiable organic or anatomical causes (e.g., no endocrine, metabolic, anatomical, or neuromuscular dysfunction). No additional diagnostic testing is required for inclusion. Ability to complete daily diaries and TTNS sessions, either independently or with caregiver support. Documented failure of conservative medical treatment following at least three months of therapy. Exclusion Criteria: Malformations of the digestive system or rectal anatomical anomalies (e.g., large intestinal atresia or stenosis, Hirschsprung's disease, congenital anorectal malformations). Neurological or psychiatric conditions (e.g., cerebral palsy, spina bifida, intellectual disability, anorexia nervosa). Major cognitive impairments. Metabolic disorders (e.g., diabetes mellitus, diabetes insipidus, scurvy, phenylketonuria). Endocrine disorders (e.g., hypothyroidism). Cardiovascular conditions such as heart disease or arrhythmias, or presence of ventriculoperitoneal shunts or cardiac pacemakers, due to potential electrical interference. History of thoracic or abdominal surgery. Presence of dermatological lesions in the area of electrode application. Presence of active electronic implants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | The transcutaneous posterior tibial nerve stimulation device | In addition to their conventional treatment, subjects in both TTNS groups will complete eight weeks of home TTNS treatment (3 sessions per week), and each session will last for 20 minutes. Stimulation will be provided by a portable device (Chattanooga®, ContinuumTM, Hixson, TN, USA). The device will be pre-programmed to apply a bi-phasic squared wave with a pulse width of 200μsec, and a pulse frequency of 20 Hz. These are default settings for TTNS that have been used in previous studies for urinary and fecal incontinence59,62,67. Two self-adhesive electrodes (5 x 5 cm) will be placed over the ankle area, one approximately 3 to 4 cm above the medial tibial malleolus and a second electrode just below the medial malleolus of the same leg. |
| OTHER | PSUS | Handheld US |
Timeline
- Start date
- 2024-02-21
- Primary completion
- 2026-02-25
- Completion
- 2026-02-25
- First posted
- 2025-07-22
- Last updated
- 2025-07-22
Locations
1 site across 1 country: Israel
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT07077044. Inclusion in this directory is not an endorsement.